Servier muscular dystrophy drug fails trial
An experimental medication for Becker muscular dystrophy failed to slow the progression of the disease in a major clinical study.
FTMQ Health, written by our newsroom0 views
The French pharmaceutical company Servier announced on November 3, 2026, that an experimental drug intended to treat a rare form of muscular dystrophy failed its trial. STAT News reported that the drug, named sevasemten, did not slow the progression of Becker muscular dystrophy in a long placebo controlled trial. [1]
According to STAT News, the outcome of the study, named the GRAND CANYON study, was unexpected because the drug had previously shown promising results in a smaller randomized trial. Servier stated that the results from this pivotal trial were not aligned with findings from earlier clinical studies. [1]
The drug was originally developed by Edgewise Therapeutics before Servier acquired it in June for 1.55 billion dollars in cash, alongside up to 1 billion dollars in potential milestone payments. Patients diagnosed with Becker muscular dystrophy currently have no approved treatment options available to them. [1]
Servier Laboratories is an international pharmaceutical company with headquarters located in Suresnes, France. It was founded by Jacques Servier and is governed by a non profit foundation. [2]
In short
- Servier announced that its experimental drug sevasemten failed to slow Becker muscular dystrophy in a placebo-controlled trial.
- Patients diagnosed with Becker muscular dystrophy currently have no approved medical treatments.
- Servier purchased the drug from Edgewise Therapeutics for 1.55 billion dollars in cash plus potential milestone payments.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]STAT+: Servier’s $1.55 billion muscular dystrophy drug fails first major testSTAT News, 9h ago (the report this story comes from)
Background
- [2]Laboratoires Servier on Wikipedia
Our newsroom writes these reports with the help of software, from the 2 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Cancer trial drug may target tumors differently than originally believedTop Stories, 28d ago
- Abbott experimental sound wave trial meets primary goals for heart diseaseMedical Science, 2d ago
- Tennessee Fails to Execute Christa Pike via Lethal InjectionHealth Care, 28d ago
- Moderna and Merck melanoma vaccine clinical trial data released earlyTop Stories, 11d ago
More in Top Stories
- Mass General Brigham CEO letter causes employee anxiety after recent layoffs6h ago
- Rural Welsh health board faces backlash over community hospital bed cuts6h ago
- Emergency department admission rates vary widely across hospitals in England6h ago
- Study finds shift in adult autism diagnoses since 20106h ago
- Washington state resident dies after contracting bird flu at dairy farm1d ago
- Monash Institute researchers target post menopause heart health with new grant1d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.
Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.